TriangleNCT01653028 · OUTCOME
Progression Free Survival (PFS)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Weeks
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- The time between registration to disease progression or death, assessed up to 18 months
What was measured
The distribution will be estimated by the methods of Kaplan and Meier. The estimates of PFS at specific time points will be calculated (eg, median, 1 year PFS).
Groups in this outcome
Cohort 1
Liposarcoma patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Cohort 2
Leiomyosarcoma patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Cohort 3
Undifferentiated Sarcoma patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Cohort 4
Malignant Peripheral Nerve Sheath Tumor patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Cohort 5
Other Sarcoma patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
| Group | Source count |
|---|---|
| Cohort 1 | 12 |
| Cohort 2 | 10 |
| Cohort 3 | 11 |
| Cohort 4 | 10 |
| Cohort 5 | 29 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Cohort 1 | 13 | Not reported | 6.29 | 37.1 | Not reported |
| Cohort 2 | 11.7 | Not reported | 1.71 | 21.9 | Not reported |
| Cohort 3 | 11.7 | Not reported | 5 | 20.6 | Not reported |
| Cohort 4 | 13.2 | Not reported | 3.57 | 45 | Not reported |
| Cohort 5 | 6.57 | Not reported | 5.86 | 18.1 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 6.29
- upper Limit
- 37.1
- value
- 13
- group Id
- OG001
- lower Limit
- 1.71
- upper Limit
- 21.9
- value
- 11.7
- group Id
- OG002
- lower Limit
- 5
- upper Limit
- 20.6
- value
- 11.7
- group Id
- OG003
- lower Limit
- 3.57
- upper Limit
- 45
- value
- 13.2
- group Id
- OG004
- lower Limit
- 5.86
- upper Limit
- 18.1
- value
- 6.57
- denoms
- counts
- group Id
- OG000
- value
- 12
- group Id
- OG001
- value
- 10
- group Id
- OG002
- value
- 11
- group Id
- OG003
- value
- 10
- group Id
- OG004
- value
- 29
- units
- Participants
- description
- The distribution will be estimated by the methods of Kaplan and Meier. The estimates of PFS at specific time points will be calculated (eg, median, 1 year PFS).
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Liposarcoma patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
- id
- OG000
- title
- Cohort 1
- description
- Leiomyosarcoma patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
- id
- OG001
- title
- Cohort 2
- description
- Undifferentiated Sarcoma patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
- id
- OG002
- title
- Cohort 3
- description
- Malignant Peripheral Nerve Sheath Tumor patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
- id
- OG003
- title
- Cohort 4
- description
- Other Sarcoma patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
- id
- OG004
- title
- Cohort 5
- param Type
- MEDIAN
- reporting Status
- POSTED
- time Frame
- The time between registration to disease progression or death, assessed up to 18 months
- title
- Progression Free Survival (PFS)
- type
- SECONDARY
- unit Of Measure
- Weeks
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice